TABLE 2.
Cost Input for the Model
Services | Rate | Cost per unit | CPT and HCPCS codes |
---|---|---|---|
Drug costs | |||
Wholesale acquisitions cost | |||
Ranibizumab 0.5 mg/0.05 mL | Manufacturer: 12, PRN: 6.9, T&E: 8, RWE: 7.23 | $1,950.00 | IBM Micromedex Red Book73 |
Aflibercept 2 mg/0.05 mL | Manufacturer: 8.02, PRN: 5.1, T&E: 8, RWE: 7.04 | $1,850.00 | IBM Micromedex Red Book73 |
Bevacizumab 1.25 mg/0.05 mL | Manufacturer: 12, PRN: 7.7, T&E: 8.9, RWE: 6.91 | $73.20 | IBM Micromedex Red Book73 |
Brolucizumab 6 mg/0.05 mL | Manufacturer: 7.01, PRN: 7.13, T&E: 7.13, RWE: 5.55 | $1,850.00 | IBM Micromedex Red Book73 |
Average sales price | Same rate as used for WAC | ||
Ranibizumab 0.5 mg/0.05 mL | $1,376.00 | HCPCS J277880 | |
Aflibercept 2 mg/0.05 mL | $1,826.00 | HCPCS J017880 | |
Bevacizumab 1.25 mg/0.05 mL | $73.00 | IBM Micromedex Red Book73 | |
Brolucizumab 6 mg/0.05 mL | $1,872.00 | HCPCS J017980 | |
Administration costs | |||
Cost of intravitreal injection in 1 eye | Based on the treatment regimen | $114.20 | CPT 6702874 |
Cost of intravitreal injection in both eyes (1.5x the cost of 1 eye) | — | $171.30 | Medicare multiple surgery payment guidelines75,76 |
Physician visits | |||
Cost of an initial office visit | 1 | $169.57 | CPT 9920474 |
Cost of subsequent office visit | PRN is monthly; other regimens rate is determined by dosages | $128.39 | CPT 9201474 |
Lab and disease monitoring costs | |||
Optical coherence tomography at each visit | PRN is monthly; other regimens rates is same as their dosages | $41.18 | CPT 9213474 |
Fluorescein angiography, at initial evaluation | 1 | $127.70 | CPT 92235,74 rate assumed to be one for the first visit |
Cost of fluorescein angiography involving fellow eye (2x the cost of 1 eye) | $255.40 | Assumed based on a study Yu et al (2021)67 |
CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; PRN = pro re nata; RWE = real-world evidence; T&E = treat and extend; WAC = wholesale acquisitions cost.